Abstract
The intestinal uptake mechanism of the purine analogue, acyclovir, was investigated in rat jejunum using in vitro and in situ methods. The pyrimidine, uracil, was used as a reference compound for carrier-mediated transport, while the purine analogue, caffeine, served as the reference compound for passive diffusion. With the in vitro intestinal ring method, acyclovir uptake was linear in the concentration range 0.01–5 mM. No significant competition for uptake was observed with uracil, 6-mercaptopurine, hypoxanthine, caffeine, or adenine. In addition, use of 2,4-dinitrophenol (DNP), ouabain, or K+ substituted buffer did not reduce the rate of acyclovir uptake. The in situ single-pass perfusion method yielded a wall permeability of ∼0.2, which did not vary consistently with increasing concentration. Coperfusion of acyclovir with DNP did not decrease the wall permeability. None of the data provided evidence of a carrier-mediated transport system, and it was concluded that the uptake mechanism of acyclovir in the rat jejunum is predominantly via passive diffusion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
A. G. Gilman, L. S. Goodman, T. W. Rall, and F. Murad (eds.). The Pharmacological Basis of Therapeutics, MacMillan, New York, 1986, pp. 1229–1231.
W. H. Miller and R. L. Miller. J. Biol. Chem. 255(15):7204–7207 (1980).
P. de Miranda and M. R. Blum. J. Ant. Chemo. 12(B):29–37 (1983).
P. de Miranda, H. C. Krasny, D. A. Page, and G. B. Elion. Am. J. Med. Acyclovir Symp. 31–55 (1982).
L. S. Schanker and D. J. Tocco. J. Pharm. Exp. Ther. 128:115–120 (1960).
L. S. Schanker and D. J. Tocco. Biochim. Biophys. Acta. 56:469–473 (1962).
J. R. Bronk and J. G. Hastewell. J. Phys. 382:475–488 (1986).
M. I. Shaw and D. S. Parsons. Clin. Sci. 66:1–212 (1960)
V. S. Patel and W. G. Kramer. J. Pharm. Sci. 75(3):275–277 (1986).
R. D. Berlin and R. A. Hawkins. Am. J. Phys. 215(4):932–941 (1968).
J. Blanchard, D. F. Perry, and P. D. Watson. Int. J. Pharm. 18:259–268 (1984).
D. W. Wilson and H. C. Wilson. J. Biol. Chem. 237(5):1643–1647 (1962).
J. H. Oh, J. B. Dosseter, and I. T. Beck. Can J. Phys. Pharm. 45:121–127 (1967).
C. E. Dukes, C. A. Steplock, A. M. Kahn, and E. J. Weinman. Proc. Soc. Exp. Biol. Med. 171:19–23 (1982).
J. Knapowski, W. Adam, C. Arasinowicz, and K. Weiss. Acta. Med. Polona 4:201–207 (1963).
N. Kolassa, W. G. Schutzenberger, H. Weiner, and K. Turnheim. Am. J. Phys. 238:G141–G149 (1980).
E. Scharrer, W. Raab, W. Tiemeyer, and B. Amann. Pflugers Arch. 391:41–43 (1981).
A. H. Khan, S. Wilson, and J. C. Crawhall. Can. J. Phys. Pharm. 53:113–119 (1975).
A. Sasaki, J. Nakamura, R. Konishi, and J. Shibasaki. Chem. Pharm. Bull. 34(10):4265–4272 (1986).
W. R. Ravis, J. W. Wang, and S. Feldman. Biochem. Pharmacol. 33:443–448 (1984).
D. Brigden, A. Fowle, and A. Rosling. In L. H. Collier and J. Oxford (eds.), Developments in Antiviral Therapy, Academic Press, London, 1980, pp. 53–62.
G. L. Amidon, B. H. Stewart, and S. Pogany. J. Cont. Release 2:13–26 (1985).
R. L. Elliott, G. L. Amidon, and E. N. Lightfoot. J. Theor. Biol. 87:757–771 (1980).
P. de Miranda, H. C. Krasny, D. A. Page, and G. B. Elion. J. Pharm. Exp. Ther. 219(2):309–315 (1981).
R. L. Pisoni, K. S. Flickinger, J. G. Thoene, and H. N. Christensen. J. Biol. Chem. 262(13):6010–6017 (1987).
B.W. Katgely, R. J. Bridges, and W. Rummel. Biochim. Biophys. Acta 832:429–434 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meadows, K.C., Dressman, J.B. Mechanism of Acyclovir Uptake in Rat Jejunum. Pharm Res 7, 299–303 (1990). https://doi.org/10.1023/A:1015890516119
Issue Date:
DOI: https://doi.org/10.1023/A:1015890516119